The most critical finding of our in vivo study was that Gps improved CUMS-induced depression-like behavior through promoting microglial states into the anti-inflammatory phenotypes likely by inhibiting the TLR4/MyD88/NF-κB signaling pathway (Figure 8). Here, MYD88 is linked to depressive symptom measurement.